SEC Form 4 · accession 0001209191-18-011604
Adverum Biotechnologies, Inc. · ADVM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer C. Cheng
Officer — General Counsel
Period of report
Feb 15, 2018
Accepted (ET)
Feb 20, 2018 · 7:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501756
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.40 | Feb 15, 2018 | A | 114,000 | A | — | Feb 14, 2028 | Common Stock | 114,000 | 114,000 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 15, 2018 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.